ASX Penny Stocks To Consider In September 2026

The Australian market is poised for a cautious rebound, with the ASX set to open higher despite global challenges like rising oil prices and higher bond yields. In this context, identifying stocks with strong fundamentals becomes crucial for investors seeking stability and potential growth. While the term "penny stock" might seem outdated, it still signifies smaller or emerging companies that can offer significant opportunities. By focusing on those with robust financials and clear growth paths, investors can find promising options within this category.

Here's a peek at a few of the choices from the screener.

Echelon Resources (ASX:ECH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Echelon Resources Limited is involved in the exploration and production of oil and gas properties in New Zealand and Australia, with a market cap of A$80.65 million.

Operations: The company generates revenue from its operations in the Kupe Oil & Gas Field with A$7.12 million and the Amadeus Basin Oil & Gas Fields contributing A$56.24 million.

Market Cap: A$80.65M

Echelon Resources has demonstrated significant financial improvement, becoming profitable this year with a net income of A$24.44 million, up from A$3.23 million the previous year. The company reported sales of A$63.36 million for the fiscal year ending June 2026, driven by its operations in the Kupe and Amadeus Basin Oil & Gas Fields. Despite not declaring a final dividend, Echelon's robust cash position exceeds its total debt, ensuring strong coverage for liabilities and interest payments. The management and board are experienced with long tenures, contributing to stable governance amidst low return on equity figures.

• Jump into the full analysis health report here for a deeper understanding of Echelon Resources.
• Assess Echelon Resources' previous results with our detailed historical performance reports.

Kinatico (ASX:KYP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Kinatico Ltd operates in Australia and New Zealand, offering screening, verification, and SaaS-based workforce management and compliance technology systems, with a market cap of A$56.76 million.

Operations: The company generates A$35.56 million in revenue from providing screening and verification checks.

Market Cap: A$56.76M

Kinatico Ltd has shown promising financial performance, reporting A$35.17 million in sales for the year ending June 2026, up from A$32.13 million the previous year, with net income rising to A$2.01 million. The company's earnings have grown consistently over five years and are forecasted to continue growing at a notable rate of 43.98% annually. Kinatico's debt-free status and strong asset position ensure short-term liabilities are well-covered, while its experienced management team supports stable operations despite low return on equity figures. Trading significantly below estimated fair value suggests potential upside for investors seeking undervalued opportunities in this sector.

• Take a closer look at Kinatico's potential here in our financial health report.
• Explore Kinatico's analyst forecasts in our growth report.

Singular Health Group (ASX:SHG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Singular Health Group Ltd is a healthcare technology company operating in Australia with a market capitalization of A$61.96 million.

Operations: The company generates revenue primarily from the provision and development of its 3Dicom Software Medical Technology, amounting to A$1.90 million.

Market Cap: A$61.96M

Singular Health Group Ltd, with a market capitalization of A$61.96 million, remains pre-revenue despite generating A$1.90 million from its 3Dicom Software Medical Technology. The company is unprofitable, with losses slightly decreasing to A$6.34 million for the year ending June 2026. Despite this, Singular Health maintains a strong cash position with short-term assets significantly exceeding liabilities and no debt on its balance sheet. Management and board members bring experience to the table, contributing to operational stability amid high volatility in share prices. The company's financial runway appears sufficient for over a year even if cash flow reductions persist.

• Click here to discover the nuances of Singular Health Group with our detailed analytical financial health report.
• Gain insights into Singular Health Group's historical outcomes by reviewing our past performance report.

Turning Ideas Into Actions

• Unlock more gems! Our ASX Penny Stocks screener has unearthed 392 more companies for you to explore.Click here to unveil our expertly curated list of 395 ASX Penny Stocks.
• Ready To Venture Into Other Investment Styles? These 27 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com